![Syndax Pharmaceuticals, Inc. logo](/logos/SNDX.webp)
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Overview | Financials
Company Name | Syndax Pharmaceuticals, Inc. |
Symbol | SNDX |
Currency | USD |
Price | 19.1 |
Market Cap | 1,625,341,240 |
Dividend Yield | 0% |
52-week-range | 11.215 - 25.34 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael A. Metzger M.B.A. |
Website | https://www.syndax.com |
An error occurred while fetching data.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD